Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,394 | 0,474 | 07:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13:54 | Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type | 22 | PMLiVE | ||
Mi | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED RESULTS ON MODEL-INFORMED DOSE SELECTION FOR PIMICOTINIB AT ACOP 2024 | 1 | HKEx | ||
Di | Abbisko: Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial | 75 | PR Newswire | - The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant... ► Artikel lesen | |
ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
Di | ABBISKO-B (02256): INSIDE INFORMATION - POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 MANEUVER STUDY OF PIMICOTINIB IN TGCT PATIENTS AND UPDATED RESULTS ... | 1 | HKEx | ||
Fr | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT PRELIMINARY PHASE 2 STUDY RESULTS OF PIMICOTINIB FOR THE TREATMENT OF CGVHD ... | 2 | HKEx | ||
23.10. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED PRECLINICAL RESEARCH RESULTS OF ITS PRMT5*MTA AND ORAL KRASG12D PROGRAMS AT ... | - | HKEx | ||
30.09. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL | - | HKEx | ||
30.09. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE AND REPURCHASED SHARES CANCELLATION | 1 | HKEx | ||
24.09. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABK3376 OBTAINED IND APPROVAL FROM NMPA | - | HKEx | ||
19.09. | ABBISKO-B (02256): 2024 INTERIM REPORT | 1 | HKEx | ||
30.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
22.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
14.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
12.08. | ABBISKO-B (02256): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
26.07. | ABBISKO-B (02256): DATE OF BOARD MEETING | 1 | HKEx | ||
10.07. | ABBISKO-B (02256): POSITIVE PROFIT ALERT | - | HKEx | ||
04.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | 1 | HKEx | ||
03.07. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL | 1 | HKEx | ||
28.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
28.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - 2024 ESMO-GI | ABBISKO THERAPEUTICS PRESENTS NEW PHASE II CLINICAL DATA OF IRPAGRATINIB IN COMBINATION WITH ... | 1 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,610 | +1,01 % | DAX-Check LIVE: Daimler Truck, Delivery Hero, Heidelberg, Lanxess, Munich Re, Nordex, Qiagen & Co. | Nachdem gestern feststand, dass Donald Trump die US-Wahl für sich entschieden hat, stieg der DAX zunächst um rund 1,5 Prozent an. Doch dann trat schnell Ernüchterung ein. Am Ende gab der DAX 1,13 Prozent... ► Artikel lesen | |
EVOTEC | 8,590 | +0,29 % | Evotec Aktie: Positive Entwicklungen machen Freude! | Die Evotec-Aktie erlebte am Montag einen bemerkenswerten Aufschwung an der Börse. Der Kurs des Hamburger Biotechnologieunternehmens schoss um mehr als 22% in die Höhe und erreichte 9,28 Euro. Auslöser... ► Artikel lesen | |
BIONTECH | 108,80 | +3,03 % | BioNTech Aktie: Sonnige Zeiten voraus! | Die BioNTech-Aktie erfährt einen bemerkenswerten Aufschwung, nachdem die renommierte US-Investmentbank Goldman Sachs ihre Einschätzung von "Neutral" auf "Buy" angehoben hat. Diese Neubewertung geht... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 52,55 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
GUBRA | 91,00 | +40,00 % | AKTIONÄR-Depotwert Gubra wird optimistischer - richtungsweisende Daten in Kürze | Der dänische Wirkstoffforscher Gubra hat ein weiteres wachstumsstarkes Quartal abschließen können - vor allem dank dynamischer Entwicklungen in den Forschungsbereichen Adipositas und Nierenerkrankungen.... ► Artikel lesen | |
DYNE THERAPEUTICS | 34,150 | 0,00 % | Dyne Therapeutics GAAP EPS of -$0.96 misses by $0.25 | ||
NUVALENT | 90,27 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results | Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product... ► Artikel lesen | |
ARS PHARMACEUTICALS | 14,060 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 34,590 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,310 | 0,00 % | Recursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed Combination | Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated closeSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq:... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 19,470 | 0,00 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,77 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
LEXEO THERAPEUTICS | 7,750 | 0,00 % | Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results | Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression... ► Artikel lesen | |
ADMA BIOLOGICS | 21,470 | 0,00 % | ADMA Biologics-Aktie erreicht Allzeithoch von 21,25 US-Dollar | ||
89BIO | 8,920 | 0,00 % | 89bio slips after $125 million stock deal |